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Abstract
Despite advances in our cellular and molecular knowledge, hepatocellular carcinoma (HCC)
remains one of the major public health problems throughout the world. It is now known to be
highly heterogeneous: it encompasses various pathological entities and a wide range of clinical
behaviors, and is underpinned by a complex array of gene alterations that affect supra-molecular
processes.
Four families of HCC tumour markers have been recently proposed: a) onco-fetal and glycoprotein
antigens; b) enzymes and iso-enzymes; c) cytokines and d) genes. A category of tumour-associated
antigens called cancer-testis (CT) antigens has been identified and their encoding genes have been
extensively investigated. CT antigens are expressed in a limited number of normal tissues as well
as in malignant tumors of unrelated histological origin, including the liver. Given that cancers are
being recognized as increasingly complex, we here review the role of CT antigens as liver tumour
biomarkers and their validation process, and discuss why they may improve the effectiveness of
screening HCC patients and help in determining the risk of developing HCC.
Background
Hepatocellular carcinoma (HCC) is a common malig-
nancy affecting approximately one million of people
around the world every year and represents the fifth most
common cancer worldwide with an incidence equal to the
death rate [1-3]. The incidence of HCC is low in the occi-
dental world and high in Southeast Asia and sub-Saharan
Africa, however it has been rising in the last two decades
in Europe, United states and Japan [3,4]. Furthermore, it
is the second common cause of death in China, where its
mortality rate is 20.37/100 thousand [5].
HCC primarily affects old people, reaching its highest
prevalence among those aged 65 to 69 years old. Chronic
infection by the hepatitis B virus is the most common
cause of this neoplasia. Other important causes are cirrho-
sis, chronic viral hepatitis (hepatitis C virus, and hepatitis
B plus D viruses), alcohol abuse, obesity, hemochromato-
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sis, α1-antitripsin deficiency, and toxins similar to afla-
toxin [1,3]. Accordingly, the major clinical risk factor for
the development of HCC is liver cirrhosis since 70–90%
of HCCs develop into a cirrhotic liver. Most HCCs occur
after many years of chronic hepatitis that provides the
mitogenic and mutagenic environments to precipitate
random genetic alterations resulting in the malignant
transformation of hepatocytes and HCC development [6].
In most cases, HCC is asymptomatic and has a low life
expectancy.
Despite its significance, there is only an elemental under-
standing of the molecular, cellular and environmental
mechanisms that drive disease pathogenesis, and there are
only limited therapeutic options, many with negligible
clinical benefit [7].
As for most types of cancer, hepatocarcinogenesis is a
multi-state process involving different genetic alterations
that ultimately lead to the malignant transformation of
hepatocytes. HCCs are phenotypically (morphology and
microscopy) and genetically heterogeneous tumors, pos-
sibly reflecting in part the heterogeneity of etiologic fac-
tors implicated in HCC development. Malignant
transformation of hepatocytes may occur regardless of the
etiologic agent through a pathway of increased liver cell
turnover, induced by chronic liver injury and regeneration
in a context of inflammation, immune response, and oxi-
dative DNA damage. This may result in genetic alterations
that affect supra-molecular processes [6].
The multi-state process of hepatocarcinogenesis is com-
plex and heterogeneous and depends on a combination of
many genetic, viral, and environmental factors. Different
genes have been implicated in hepatocarcinogenesis
including genes regulating DNA damage responses, genes
involved in cell cycle control, genes involved in growth
inhibition and apoptosis, and genes responsible for cell-
cell interaction and signal transduction. The major molec-
ular features of human HCC include aneuploidy and
chromosomal aberrations, activation of proto-oncogenes,
and inactivation of tumor suppressor genes [6-9].
However, this database has been obtained largely in a
shatter and uncoordinated manner, typically in investiga-
tions in which aberrations in single genes have been ana-
lyzed in a group of HCC from humans and experimental
animals. Although these data all seems to be helpful, they
have not led to a coherent understanding of the complex
mechanisms underlying HCC development, or to the
identification of critical genomic and/or molecular aber-
rations that improve the carefulness of diagnosis or thera-
peutic interventions.
HCC is a non-linear complex disease that emerges from
multiple spontaneous and/or inherited mutations that
induce dramatic changes in expression patterns of genes
and proteins that function in networks controlling critical
cellular events [10-16]. Therefore, it is compulsory to
identify HCC and the recurrence at its earlier period. A
number of serum markers have been proposed and cur-
rently used as an effective method for detecting HCC for a
long time [17]. Four families of HCC tumour markers
have mainly been proposed and currently applied in the
clinical practice [17]. In addition, a category of tumour-
associated antigens called cancer-testis (CT) antigens has
recently been identified and their encoding genes have
been extensively investigated. CT antigens are expressed in
a limited number of normal tissues as well as in malignant
tumors of unrelated histological origin.
Given that cancers are being recognized as increasingly
complex, we here review the role of CT antigens as liver
tumour biomarkers and their validation process, and dis-
cuss why they may improve the effectiveness of screening
HCC patients and help in determining the risk of develop-
ing HCC.
HCC biomarkers: from biochemistry to 
genomics
Four distinct families of HCC tumour markers have been
proposed and currently applied in the clinical practice: (a)
onco-fetal and glycoprotein antigens; (b)  enzymes and
iso-enzymes; (c) cytokines and (d) genes [17]. However, it
is compulsory to underline that a truthful specific biomar-
ker for early detection, diagnosis or clinical outcome/
prognosis of HCC is still undiscovered.
Onco-fetal antigens and glycoprotein antigens
a) Alpha fetoprotein (AFP) is a fetal specific glycoprotein
produced primarily by the fetal liver, yolk sac and gut, in
the first trimester of pregnancy [18-20]. In normal condi-
tions, its serum concentration falls rapidly after birth and
its synthesis in adult life is repressed. Pathological eleva-
tion of AFP is seen in hepatocyte regeneration, hepatocar-
cinogenesis and embryonic carcinomas. AFP was first
described as a marker for HCC by Abelev in the 1960s [21]
and used as a serum marker for HCC in humans for many
years. It has a sensitivity of 39%–65%, a specificity of
76%–94%, and a positive predictive value of 9%–50%
[22]. However, greater than 70% of HCC patients have a
high serum concentration of AFP because of the tumor
excretion. HCC patients with a high AFP concentration (≥
400 ng/mL) tend to have greater tumor size, bilobar
involvement, massive or diffuse types, portal vein throm-
bosis, and a lower median survival rate. Though the meas-
urement of AFP serves as an important tool in screening
HCC patients, some reports have indicated that it has lim-
ited utility of differentiating HCC from benign hepaticJournal of Translational Medicine 2007, 5:3 http://www.translational-medicine.com/content/5/1/3
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disorders for its high false-positive and false-negative
rates, and patients with acute exacerbation of viral hepati-
tis but no HCC may also have markedly increased AFP lev-
els [17,23].
b) Glypican-3 (GPC3) is one of the members of heparan
sulfate proteoglycans. Although it is highly expressed dur-
ing embryogenesis and is involved in organogenesis, its
exact biological function remains unknown. It binds to
the cell membrane through the glycosyl-phosphatidyli-
nositol anchors. GPC3 is able to interact with various
growth factors that either stimulates or inhibits the
growth activity. [17,23-25]. GPC3 mRNA and protein are
expressed in >80% of human HCC but not in normal tis-
sues except for placenta and fetal liver [26]. Recently,
Nakatsura and Nishimura described GPC3 as a novel
tumor marker for human HCC [27]. It was found in sera
from 40–50% of HCC patients, although it was not
detected in sera from patients with liver cirrhosis or
chronic hepatitis, or in sera from healthy individuals [27].
Enzymes and iso-enzymes
a) Gamma-glutamyl transferase (GGTII) is a glycosylated
membrane enzyme, catalyses the transfer of Q-glutamyl
groups from peptide donors such as glutathione to a vari-
ety of acceptors including dipeptides, free amino acids or
water. GGT activity is modulated in many physiological
and pathological conditions, including differentiation
and carcinogenesis [28]. In the liver GGT is mainly
secreted in serum by macrophagic Kupffer cells and
endothelial cells of bile ducts and its activity increases in
tissues with HCC [17]. Sensitivities of GGTII have been
reported to be 74.0% in detecting HCC and 43.8% in
detecting small HCC [29]. Recently, it has been shown
that changes in GGTII occurring with changes in alcohol
consumption were similar regardless of ethnicity.
b)  Alpha-l-fucosidase (AFU) is a glycosidase primarily
found in lysosome and involved in the degradation of a
variety of fucose-containing fucoglycoconjugates [30].
The alterations of AFU catalytic activity in human cells, tis-
sues and body fluids have a diagnostic value for human
tumors including primary HCC [17,31-33], colorectal
cancer [34] and ovarian cancer [35].The deficiency of AFU
activity in female sera is probably a hereditary condition
related to higher risk of ovarian cancer [30]. The persist-
ently elevated AFU level in sera of patients with liver cir-
rhosis contributes to early detection of HCC [17,30].
c) Des-gamma-carboxyprothrombin (DCP) is an abnormal
prothrombin protein that is increased in the serum of
patients with HCC. Generation of DCP is thought to be a
result of an acquired defect in the post-translational car-
boxylation of the prothrombin precursor in malignant
cells. The reduction of gamma-carboxylase activity had
been determined to be due to defective gene expression in
HCC. In 8 large case-controlled studies, serum DCP was
found to have a sensitivity of 48% to 62%, a specificity of
81% to 98%, and a diagnostic accuracy of 59% to 84% in
differentiating patients with HCC from those with cirrho-
sis [36]. DCP is a well recognized tumor marker for HCC.
It is an abnormal product from liver carboxylation distur-
bance during the formation of thrombogen, and acts as an
autologous mitogen for HCC cell lines [17,37]. DCP was
more sensitive and specific than AFP for differentiating
HCC from nonmalignant chronic liver disease [38].
Cytokines
a) Vascular endothelial growth factor (VEGF), is an endothe-
lial cell mitogen that induces and promotes angiogenesis
and endothelial cell proliferation, which plays an impor-
tant role in regulating angiogenesis, and which was ini-
tially identified as a vascular permeability factor. VEGF
expression plays an important role in the development of
HCC. Its degree of expression has been reported to be
associated with tumor size and histological grade [17,38-
42].
b) Interleukin-8 (IL-8) is a multifunctional CXC chemok-
ine that affects human neutrophil functions, including
chemotaxis, enzyme release, and expression of surface
adhesion molecules [17]. IL-8 seems to have also direct
effects on tumor and vascular endothelial cell prolifera-
tion, angiogenesis, and tumor migration. Recently, Kubo
et al have shown that the expression of IL-8 in human
HCC has more relevance to metastatic potential, such as
vessel invasion, than to angiogenesis or cell proliferation
[43]. Moreover, significant correlations of serum IL-8 lev-
els with tumor size and tumor stage suggest that IL-8 may
be directly or indirectly involved in the progression of
HCC. These findings indicate that serum IL-8 may be a
useful biological marker of tumor invasiveness and an
independent prognostic factor for patients with HCC
[44,45].
c) Transforming growth factor-beta 1 (TGF-β1) is a multi-
functional cytokine involved in the regulation of growth
and differentiation of both normal and transformed cells.
TGF-β1 is a negative growth factor which correlates with
cellular immunosuppression during the progression of
HCC. It has been reported that TGF-β1 mRNA and its pro-
tein were over-expressed in HCC tissues, and plasma TGF-
β1 was elevated in patients with HCC. Its serum level in
HCC patients has been shown to be elevated compared
with those in healthy adults and patients with non-malig-
nant hepatopathy [17,46]. TGF-β1 mRNA was over-
expressed in HCC compared with surrounding liver tis-
sues, especially in small-sized and well-differentiated
HCCs. In the liver, endogenous factors, such as TGF-β1
may be involved in induction of apoptosis. In HCC, birthJournal of Translational Medicine 2007, 5:3 http://www.translational-medicine.com/content/5/1/3
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and death rates of cells are several times higher than in
surrounding liver. Consequently, tumor promoters may
act as survival factors, i.e., inhibit apoptosis preferentially
in precancerous and even in malignant liver cells, thereby
stimulating selective growth of precancerous lesions [47].
d) Tumor-specific growth factor (TSGF) is a product synthe-
sized and released by malignant cells. It results in blood
capillary amplification surrounding the tumor, into
peripheral blood during its growing period. Thus, the
higher presence in serum of TSGF can be used as diagnos-
tic marker in detecting HCC. Its sensitivity can reach 82%
at the cut-off of 62 UI/mL [17,48]. TSGF is the first tumor
biomarker which obtained the approval by Chinese gov-
ernment to land the market [48].
It is essential to emphasize that the quantification of
cytokines in serum/plasma, collected prior to the clinical
recognition of HCC, may provide insights into the nature
of a host immune system environment that contributes to
cancer development and/or growth. Such studies need to
be designed with knowledge of the biology of the
cytokines to be measured, and of the limitations inherent
in the measurement of these molecules. Also, many
cytokines are labile and/or are produced locally in
immune system organs and not distributed systemically,
so they cannot be detected in serum/plasma.
Genes
a) Alpha-fetoprotein mRNA (AFP mRNA) It has recently
been demonstrated that AFP mRNA expression detected
by reverse-transcription polymerase chain reaction (RT-
PCR) in peripheral blood 1 week after surgery correlated
with the recurrence of HCC and was a good predictor for
tumor recurrence [49]. In 1994, Matsumura et al. first
reported that single HCC cell in circulation could be
detected by means of RT-PCR, targeting AFP mRNA [50].
Subsequently, many investigators reported the value of
AFP mRNA as a predictor for HCC recurrence, but the
results are rather controversial. This may be due to the
blood-borne dispersion of both tumor cells and normal
liver cells during surgical manipulation and the mis-tran-
scription of mRNA encoding AFP by peripheral mononu-
clear cells.
b) Gamma-glutamyl transferase mRNA (GGT mRNA) can be
detected in the serum and liver tissues of healthy adults or
patients with HCC, non-malignant hepatopathy, hepatic
benign tumor, and secondary tumor of the liver [17]. The
genetic regulation of GGT is complex. The human enzyme
is encoded by a multi-gene family that includes at least
seven genes, but only one (gene I) appears to code for an
active enzyme. These mRNA products are named after the
organs or cells from which they were first characterized:
mRNA firstly described in fetal liver (type A), the mRNA
isolated from the human hepatoma cell line HepG2 cells
(type B) and the mRNA isolated from human placenta
(type C) [28]. Type A is predominantly expressed in nor-
mal liver tissues or liver tissues without malignant hepat-
opathy, benign tumor or secondary liver cancer. On the
contrary type B is commonly found in cancerous tissues of
HCC. Sheen et al. have demonstrated that patients of HCC
with type B gamma-GTP mRNA both in cancer and in
non-cancerous tissue had a worse outcome, earlier recur-
rence, and more post-recurrence death [51]. The authors
suggested that HepG2 mRNA might be of diagnostic value
[52].
c)  Human telomerase reverse transcriptase mRNA (hTERT
mRNA) has been shown to be a rate-limiting determinant
of the enzymatic activity of human telomerase. Human
telomerase is a ribonucleoprotein that has three major
components: human telomerase RNA component
(hTERC); human telomerase-associated protein 1
(hTEP1); and human telomerase reverse transcriptase
(hTERT). Of the three components, hTERT is the catalytic
subunit responsible for telomerase activity. Telomerase is
expressed in most human cancers and immortal cell lines
but is inactive in normal somatic cell lines or tissue.
Recent reports support the concept that activation of tel-
omerase may be an important and obligate step in the
development of most malignant tumors, including
human HCC [53]. Telomerase activity is closely correlated
with hTERT expression. A weak expression of hTERT and
telomerase activity was observed in 30% of non-cancerous
tissues, while strong hTERT expression and enzyme activ-
ity were observed only in HCC. The cellular origin of
hTERT expression in non-cancerous liver is still controver-
sial, because infiltrating lymphocytes, precancerous liver
parenchymal cells, and harboring micro-metastases of
cancer cells may be responsible. This ambiguity makes the
value of hTERT transcripts in the diagnosis of HCC and
the feasibility of the promoter in gene therapy uncertain
[54-56].
d) Insulin-like growth factor II-mRNA (IGF-II) Recently, it
has been shown that the abnormal expressions of IGF-II
mRNA might be a useful tumor marker for HCC diagno-
sis, differentiation of extra-hepatic metastasis and moni-
toring postoperative recurrence. Moreover, serum IGF-II
level seems to be an independent serologic marker or a
complementary tumor marker to AFP for diagnosis of
small HCC [57].
It can be stressed that several other biomarkers have been
proposed and preliminarily used in the early detection of
HCC. AFP and DCP are, however, the most useful serum
tumor markers for detection of HCC, and the simultane-
ous determination of these markers might improve theJournal of Translational Medicine 2007, 5:3 http://www.translational-medicine.com/content/5/1/3
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accuracy, especially in differentiating HCC from precan-
cerous lesions, and nonmalignant hepatopathy.
A family of tumour-associated antigens (TAAs) has recently
been identified and their encoding genes have been exten-
sively investigated. Among them CT antigens are
expressed in a limited number of normal tissues as well as
in malignant tumors of unrelated histological origin
(including HCCs), and are being vigorously pursued as
targets for new therapeutic strategies. They are also being
evaluated because of their role in oncogenesis and the
recapitulation of portions of the germ line gene-expres-
sion program, which might contribute characteristic fea-
tures to the neoplastic phenotype such as immortality,
invasiveness, immune evasion, hypomethylation and
metastatic capacity.
The discovery of tumour-associated antigens
One of the most controversial issues in immunology for
over a century has been whether an effective immune
response can be elicited against malignant tumors [58].
Based on recent immunological developments, there is no
doubt that the immune system can recognize and elimi-
nate malignant cells. In 1967 Frank Macfarlane Burnet
introduced a general hypothesis suggesting that lym-
phocytes are continually patrolling tissues and eliminat-
ing transformed cells, presumably via recognition of
TAAs, a process he called "immunosurveillance" [59]. It is
known today that the immune system is capable of dis-
criminating between benign and malignant cells based on
specific recognition of aberrantly expressed proteins or
peptide fragments in the context of major histocompati-
bility complex (MHC).
Thus, the proteins encoded by abnormally expressed
genes of a tumour cell may represent potential targets for
immune cells, serving as tumour-associated rejection or
regression antigens. With the exception of melanoma, few
candidate TAAs have been described for human malig-
nancies [60,61].
The introduction of a genetic approach of T-cell epitope
cloning and subsequently an innovative method through
the serological analysis of recombinant tumor cDNA expression
libraries with autologous serum (SEREX) has greatly
expanded the identification of a promising class of TAAs
called CT antigens. Many TAAs have been identified using
a genetic approach in which a cDNA library from tumour
cell mRNA is generated in a eukaryotic expression system.
Bacterial generated pools of cDNA, containing between
50–200 individual clones, are co-transfected with a con-
struct encoding the appropriate MHC I gene into a highly
transfectable eukaryotic cell line. The cells transfected
with the cDNA pools are then investigated for their ability
to stimulate cytokine release from tumour reactive CTL
[62]. Single clones are isolated and the peptide epitopes
derived from these antigens are identified through the use
of HLA peptide-binding motif algorithms [63]. SEREX is a
valid alternative molecular approach for TAAs discovery.
Unlike molecular approaches that attempt to ascribe
immunity to cloned genes, SEREX employs patient sera
and autologous tumors to identify TAAs that have elicited
high titer IgG antibodies in patients demonstrating
immunity to the antigen. This approach has identified a
number of gene products that have relevance to tumour
development as well as other antigens that may be poten-
tial targets for cancer vaccines. Some of the TAAs discov-
ered using SEREX that may be useful, as vaccines include
antigens cloned from small cell carcinoma, colon cancer
and breast cancer. Another method used in the search for
TAAs is acid elution of peptides from tumour-cell surface MHC
I molecules. Pools of peptides are produced, fractioned
with high pressure liquid chromatography, and
sequenced [63,64]. The peptides are subsequently tested
for their ability to sensitize targets to enable recognition
by specific T cells. TAAs that are over-expressed or up-reg-
ulated in cancer cells can also be identified by analysis of
differentially expressed genes in tumour cells compared to
their counterpart normal cells. Serial analysis of gene expres-
sion (SAGE) is a useful approach to determine the expres-
sion of a high number of genes simultaneously. There are
many benefits to SAGE, firstly the ability to evaluate the
expression pattern of many genes in a quantitative man-
ner without prior sequence information. SAGE can deter-
mine the abundance of mRNAs and can also detect small
differences in expression levels between samples. The
SAGE method is based on two main concepts: a) a short
sequence tag consisting of 9–10 base pairs (bp) is used to
identify a transcript; b) serial units of short sequence tags
allow the efficient analysis of transcripts by the sequenc-
ing of multiple tags with a single clone. Since the intro-
duction of differential display by Liang and Pardee [65],
the rate at which differentially expressed genes have been
identified has dramatically increased. The abundance of
genes is a result of the simplicity and sensitivity of differ-
ential display and also the capability of this method to
compare multiple RNA samples in order to distinguish
between up-regulated and down-regulated genes without
knowing their sequences. Differential display employs
PCR and DNA gel electrophoresis: compared to other
methods, it is more sensitive and only a few picograms of
total RNA is needed, and results are highly reproducible
from run to run (>90%).
Cancer-testis antigens: a new class of 
biomarkers
CT antigens represents a category of TAA normally
expressed in male germ cells but not in adult somatic tis-
sues [66]. Since the restricted CT expression profile, the
presence of multi-gene family, and the X chromosomalJournal of Translational Medicine 2007, 5:3 http://www.translational-medicine.com/content/5/1/3
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location of all the SEREX identified antigens, has been
originally proposed the term of CT antigen to encompass
the heterogeneous group of antigens. Although, earlier
studies of CT antigens defined common features of these
antigens, namely the cancer/testis-restricted expression
profile, presence of multi-gene families, mapping to the X
chromosome, and immunogenicity in cancer patients,
subsequently additional features have been identified.
Among them: (a)  heterogeneous protein expression in
cancer; (b) correlation of mRNA expression with tumour
progression and with tumors of higher malignant poten-
tial; (c) in vitro activation by hypomethylation and/or his-
tone deacetylation.
Actually, 44 distinct CT "gene" or "antigen" families have
been reported in literature. Certain CT gene families con-
tain multiple members, as well as splice variants and
today a total of 89 distinct transcripts are know to be
encoded by CT genes [67]. By comparing CT antigen
expression data the following comments have been made
[67]:
￿ the expression frequency of a single CT antigen is highly
variable in different tumors type;
￿ the frequency of different CT antigen expression in a
tumour type can be different;
￿ there is a tendency for CT antigen expression to be clus-
tered, i.e. certain tumour specimens are found to express
multiple CT antigens simultaneously, whereas other
tumors will be totally negative for CT antigens.
Excluding nervous system and pancreatic cancers, which
have been still insufficiently [68,69] studied with regard
to CT transcript expression, the tumour types can be dis-
tinct in three distinct groups on the basis of the number of
CT genes expressed and their expression frequency:
a) high CT expressors: tumors which express more than
50% of the CT-antigens;
b) moderate CT expressors: tumors which express between
30–50% of the CT transcripts;
c) low CT expressors: tumors which express less than 30%
of the CT transcripts.
These data are taken from mRNA expression frequencies,
which do not necessarily directly correlate with protein
expression frequencies. Discrepancies between gene and
protein expression frequencies may reflect variations in
tissue sampling, tumour heterogeneity or different level of
sensitivity of detection. The expression of these antigens
may however correlate with advanced stage and grade of
tumors, and the presence of spontaneous immune reactiv-
ity to these antigens has been shown to correlate with
improved prognosis in some studies.
Cancer-testis antigens expression in HCC
A number of CT antigens have been found expressed with
a high percentage and specificity in HCC and their prod-
ucts are promising targets for antigen-specific immuno-
therapy of this tumor. Moreover, the high frequent co-
expression of multiple members of CT antigens in HCC
provides possibility of polyvalent vaccinations for HCC.
Zhao et al reported that of 105 HCC tissues, MAGE1, SSX-
1, CTp11 and HCA587 mRNA expressions were detecta-
ble in 75.2%, 72.4%, 62.9% and 56.2% of HCC samples,
respectively [70]. About 93.3%, 72.4%, 48.6% and 37.1%
of HCC tissues positively expressed at least one, two,
three, and four members of CT antigens, respectively.
Conversely, only SSX-1 could be detectable in 2.9% of the
corresponding adjacent non-HCC tissues in which no
metastatic lesion was found. Interestingly, in that study
the serum AFP was normal (< 20 ng/mL) or slightly ele-
vated (< 40 ng/mL) in 30.0% of HCC patients. In these
patients, 91% had MAGE-1, SSX1, CTp11 or HCA587
transcripts in their HCC tissues, suggesting applying their
mRNAs as tumour-specific markers to detect HCC cells in
circulation might be an adjuvant diagnostic tool [70].
The expression of the CT antigens mRNA was also investi-
gated by Wu et al. in the tissues of HCC and corresponding
peripheral blood of 37 patients with HCC [70]. Fifteen
samples of cirrhotic tissues and 15 normal tissues were
examined with the same method. Two kinds of CT anti-
gens (SSX-2 and SSX-5) showed high-specific and high-
frequent expression in HCC tissues, but neither of them
could be detected in adjacent non-HCC tissues. In corre-
sponding peripheral blood of HCC tissues, the positive
expression rate of the SSX-2 and SSX-5 mRNA was not
very high. No relationship was found between the expres-
sion of CT antigens and clinical indicators such as age, sex,
tumor size, TNM staging, serum AFP level and infection
with hepatitis virus [71]. In 15 patients with cirrhosis and
15 other non-tumor patients, none of the SSX-2 and SSX-
5 mRNA was detected in liver tissue or peripheral blood.
High frequency and specificity of CT antigens in HCC
indicates that their products may be new potential prom-
ising targets for antigen-specific immunotherapy of HCC.
Moreover, the high frequent co-expression of the two
genes in HCC provides a possibility of polyvalent vaccina-
tions for this neoplasia. Specific expression of CT antigens
was observed in AFP-negative HCC, suggesting the appli-
cation of their mRNA as tumor markers to detect circulat-
ing HCC cells, as adjuvant diagnostic tool, and as
indicators of recurrence and prognosis. Peng et al. found
that the expression of MAGE-A3, SSX-1, SSX-2, SSX-4,Journal of Translational Medicine 2007, 5:3 http://www.translational-medicine.com/content/5/1/3
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MAGE-B2, MAGE-C1, and MAGE-C2 correlated signifi-
cantly with older age [72]. Moreover, the expressions of
MAGE-A4 and SCP-1 were related to AFP abnormality,
and the expression of NY-ESO-1 was related to early
tumor stage [72]. There was no correlation observed
between the expression of CT antigens and the sex, HBV
infection or tumor size [72].
In search for genes associated with HCC by cDNA micro-
array, Yin et al. found that the transcription of TSPY, "tes-
tis-specific protein Y-encoded", was up-regulated in HCC,
and that TSPY is a novel CT antigen which might be serve
as a potential candidate in vaccine strategy for immuno-
therapy in HCC patients [73].
NY-ESO-1 and LAGE-1 are expressed in a high percentage
of HCC, especially in cases with metastasis [74]. It is thus
possible that also NY-ESO-1/LAGE-1 might serve as tar-
gets for antigen-specific immunotherapy in HCC and NY-
ESO-1 peptide vaccination may be of use for patients with
advanced HCC [74]. Positive rate of NY-ESO-1 mRNA was
27.4% in HCC; it was higher in HCC with tumor embolus
of portal vein than in HCC without tumor embolism
(40.0% versus 18.9%). Positive rate of NY-ESO-1 protein
was 18.9% in HCC tissue micro-array; it was significantly
higher in HCC with metastasis than in HCC without
metastasis (29.6% versus 11.5%,). Positive rates of NY-
ESO-1 mRNA and protein were 28.3% and 19.1% respec-
tively in HBsAg positive HCC, and were 29.5% and 20.7%
respectively in HCC with AFP of > 20 ng/ml. Both NY-
ESO-1 mRNA and protein were not detected in adjacent
normal liver tissue [75].
Recently, Shi et al. identified another antigen of great
interest called transgelin 2 [76]. The over-expression of
transgelin 2 mRNA in a large per cent (69%) of HCC
points to its potential as a diagnostic marker for this can-
cer.
Li et al showed that in HCC specimens the HCA587 (the
HCA587 gene, identified by SEREX from a HCC patient,
encodes a new member of CT antigens) protein was
expressed in 37.1% samples. The expressed protein was
either detected in the cytoplasm or nucleus depending on
the individual samples. More importantly, there appears
to be correlation between the tumor differentiation of
HCC and HCA587 protein expression, i.e., the lower dif-
ferentiation, the higher percentage of protein expression
[77].
From the data of Luo et al. it appears that about >80% of
the patients with HCC would be eligible for specific
immunotherapeutic approaches with at least one CT anti-
gen in ways similar to those currently being evaluated in
malignant melanomas, which express CT antigens at a
similar frequency as HCC [78]. While all patients with a
tumor expressing a given CT antigen would be candidates
for vaccine strategies using whole antigenic proteins, the
percentage of patients eligible for peptide-specific vacci-
nation would be much lower, since it requires antigenic
peptides with binding motifs restricted to specific MHC
alleles.
Concluding remarks
It is indubitable that there is a growing interest in identi-
fying diagnostic tools that could complement standard
histopathology to determine the presence of cancer cells
in tissues [79]. In particular, a pressing need exists for
biomarkers useful for early cancer detection, accurate pre-
treatment staging, prediction of response to treatment,
and monitoring of disease progression [80].
The availability of a suitable serological marker to distin-
guish between HCC and benign liver lesions would be
very useful for early diagnosis. The only serological
marker currently widely used for the diagnosis of HCC is
AFP. However, the sensitivity of this marker is limited. In
addition, AFP is not always elevated in the early stages of
cancer development, when therapy is mostly effective.
Given the high heterogeneity of HCC, it is currently
thought that an optimal serological test for HCC will be
based on the simultaneous measurement of two or three
highly specific serological markers [24].
Although several studies have proposed many serum
markers, everyone agrees that it is difficult to accurately
diagnose early HCC. But early detection is still the only
way to improve mortality – the disease is nearly always
fatal once the tumors are no longer amenable to surgical
or ablative approaches [81] In an effort to find a more reli-
able serum test for early HCC the National Cancer Insti-
tute has launched a 2-years study to validate the
usefulness of DCP as a molecular marker [81]. In Japan,
where HCV causes 80% of HCC and HBV causes another
10%, have been implemented guidelines describing an
ideal screening program for high-risk patients. The pro-
gram consists of checking the tumor markers AFP and
DCP every month, performing abdominal ultrasonogra-
phy every three months, and performing abdominal com-
puted tomography every 6 months.
There is growing evidence for a link between the immune
system and the control of cancer. Emerging evidence indi-
cate, however, that the markers would need to be studied
for each tumor type. Since the markers studied to date are
not universally prognostic, further details in approaches
for studying these markers are warranted.
Although a number of CT antigens have been discovered
and it has been suggested that some of them could beJournal of Translational Medicine 2007, 5:3 http://www.translational-medicine.com/content/5/1/3
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helpful in the early detection of HCC, the complexity of
human beings leads us to reflect on the need to establish
compelling new criteria for validating their real applica-
bility.
Biological complexity can be intuitively appreciated – at
least in terms of morphological or behavioral complexity,
or the variety of cell types in an organism – but the term
itself is notoriously difficult to define [82].
Human beings are complex hierarchical systems consist-
ing of a number of levels of anatomical organization
(genes, cells, tissues, organs, apparatuses, and organism)
that interrelate differently with each other to form net-
works of growing complexity [14,82-85].
In order to understand biology at the system level, we
need to examine the structure and dynamics of the func-
tions of organisms rather than the characteristics of their
constitutive isolated parts [82-85].
Better diagnostic methods are today needed to increase
the survival rate in liver cancer patients [86]. Proteomics
can be simply defined as the protein expression of the
genome; and protein expression can vary depending on
the biological state. Antibody microarrays can scan for
multiple targets (antigens) within the tissue or in the cir-
culation. This technology is still in its infancy and has
great potential as a diagnostic tool for hepatitis liver can-
cer patients [87]. Another proteomic approach is mass
spectrometry, which can detect proteins and present them
as charged ions. The mass spectrometric technique termed
surface enhanced laser desorption ionization (SELDI), releases
proteins in a sample from a capturing surface that can spe-
cifically bind groups of proteins which share common fea-
tures (i.e. hydrophobic, negatively charged) and the
expression of thousands of proteins can be monitored
simultaneously [87]. Interestingly, Lee et al. using SELDI
found that complement C3a was elevated in patients with
chronic hepatitis C and HCV-related HCC [88].
In the future, gene expression profiling ("disease finger-
printing") is likely to complement liver biopsy in the
molecular differential diagnosis of chronic liver diseases
and HCC. There has already been some success in the
identification of subtypes of HCC based on derived sets of
signature gene clusters [10,89].
The expression of CT in many tumoral tissues has mainly
been studied at the level of gene expression and gene level
measurement by RT-PCR analysis and the quantitative
real-time PCR (qrt-PCR) technology [90,91]. However,
the information provided by these approaches is limited
by the fact that the phenomena observed at each level of
anatomical organization have properties that do not exist
at a lower or higher level: RT-PCR and qrt-PCR may offer
a satisfactory qualitative/quantitative description of
small-scale structures, but this is likely to be irrelevant
when it comes to large-scale features.
The above considerations, in conjunction with the com-
plexity of tumor-host interactions within the tumor
microenvironment caused by temporal changes in tumor
phenotypes and an array of immune mediators expressed
in the tumor microenvironment might clarify the limited
reliability and applicability of current molecular biomar-
kers.
Despite the rapid advances that have been made in the
fields of molecular and cellular biology, there is no doubt
that cancer is still a very complex disease: it can be hypoth-
esized that each tumour is unique, and that the spectrum
of biological changes determining human tumors is infi-
nitely variable [14,85]. Carcinogenesis is a non-linear
process, whose behavior does not follow clearly predicta-
ble and repeatable pathways. Periods of inactivity may be
punctuated by sudden change, apparent patterns of
behavior may disappear and new patterns surprisingly
emerge [14,85]. Cancer is determined by a number of
processes and controls operating over much broader
scales, and by factors such as structural controls that may
operate at scales ranging from molecular to environmen-
tal. This multiple scale causality not only recognizes multi-
ple processes and controls acting at multiple scales but,
unlike a strict reductionist approach, may also recognize
the fact that relevant "first principles" may reside at scales
other than the smallest micro-scales. In other words, the
observed phenomenon at each scale has structural and
behavioral properties that do not exist at lower or higher
organizational levels [14,85].
Viewing cancer as a system that is dynamically complex in
time and space will probably reveal more about its under-
lying behavioral characteristics. This way of thinking may
further help to clarify concepts, interpret new and old
experimental data, indicate alternative experiments and
categorize the acquired knowledge on the basis of the
similitude and/or shared behaviors of very different
tumors. It is encouraging that mathematics, theoretics,
biology and medicine continue to contribute together
towards a common quantitative understanding of cancer
complexity.
To advance our knowledge in a currently widely debated
field of investigation such as that of biomarkers in HCC,
a clearer distinction must be made between in vitro labo-
ratory results (the discovery and validation of possible
biomarkers) and their real application (in vivo valida-
tion)in human beings, and it is necessary to adopt a more
complete experimental approach that forcefully includesJournal of Translational Medicine 2007, 5:3 http://www.translational-medicine.com/content/5/1/3
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both morphological and molecular techniques. Finally,
the analysis of these markers could be useful in identify-
ing patients that are most likely to benefit from immune
intervention strategies.
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